Department of Gynecology, The People's Hospital of Nanchuan, Chongqing, China.
Ginekol Pol. 2023;94(5):358-365. doi: 10.5603/GP.a2022.0034. Epub 2022 Jul 27.
This study intended to compare the safety and clinical efficacy between two treatments of uterine fibroids: laparoscopic myomectomy (LM) and high intensity focused ultrasound (HIFU).
Clinical data were collected from 587 uterine fibroid patients who were treated in The People's Hospital of Nanchuan, Chongqing from January 1, 2018 to December 31, 2019. Among the patients, 287 cases were treated with HIFU (observation group), and 300 cases were treated with LM (control group). The progression-free survival (PFS) was taken as the primary endpoint. The secondary endpoints included operation results (including operative time, intraoperative blood loss, and intraoperative fluid replacement), complications, hemoglobin level one month after surgery and clinical efficacy. In addition, the fibroid volume of the observation group before treatment and 3, 6, and 12 months after treatment were also analyzed.
The operative time of observation group was evidently shortened compared to the control group, and the intraoperative blood loss and intraoperative fluid replacement of observation group were also considerably reduced (all p < 0.05), but there was no significant difference in the hemoglobin level between the two groups one month after surgery (p > 0.05). In terms of curative effect, the total effective rate of HIFU group and LM group was 98.6% (283/287) and 95.3% (286/300) respectively, with statistically significant difference (p < 0.05). In terms of complications, the incidence of bleeding and infection in HIFU group was obviously lower than that in LM group (both p < 0.05), while no significant differences were observed in the remaining complications (all p > 0.05). Fibroid volume comparisons before treatment and 3, 6 and 12 months after operation in observation group showed that fibroid volume decreased significantly (all p < 0.05). The median follow-up time was 30.6 months. The mean PFS of patients in the observation group and control group was 29.71 months (95% CI 28.24-29.75) and 26.74 months (95% CI 26.49-28.33), respectively (HR 0.47; 95% CI, 0.29 to 0.76; Log-rank p = 0.0019).
HIFU could improve the intraoperative efficacy and reduce the complications of patients with uterine fibroids and has excellent performance in improving clinical efficacy and prolonging PFS. HIFU can be used as an alternative to surgical treatment.
本研究旨在比较两种子宫肌瘤治疗方法——腹腔镜子宫肌瘤剔除术(LM)和高强度聚焦超声(HIFU)的安全性和临床疗效。
2018 年 1 月 1 日至 2019 年 12 月 31 日期间,从重庆市南川区人民医院收集了 587 例子宫肌瘤患者的临床资料。其中 287 例接受 HIFU(观察组)治疗,300 例接受 LM(对照组)治疗。无进展生存期(PFS)为主要终点。次要终点包括手术结果(包括手术时间、术中出血量和术中液体置换)、并发症、术后 1 个月血红蛋白水平和临床疗效。此外,还分析了观察组治疗前和治疗后 3、6 和 12 个月的肌瘤体积。
观察组的手术时间明显短于对照组,术中出血量和术中液体置换也明显减少(均 p < 0.05),但术后 1 个月两组血红蛋白水平无统计学差异(p > 0.05)。在疗效方面,HIFU 组和 LM 组的总有效率分别为 98.6%(283/287)和 95.3%(286/300),差异有统计学意义(p < 0.05)。在并发症方面,HIFU 组出血和感染的发生率明显低于 LM 组(均 p < 0.05),其余并发症发生率无统计学差异(均 p > 0.05)。观察组治疗前和治疗后 3、6 和 12 个月的肌瘤体积比较显示,肌瘤体积明显减小(均 p < 0.05)。中位随访时间为 30.6 个月。观察组和对照组患者的平均 PFS 分别为 29.71 个月(95%CI 28.24-29.75)和 26.74 个月(95%CI 26.49-28.33)(HR 0.47;95%CI,0.29 至 0.76;Log-rank p = 0.0019)。
HIFU 可改善子宫肌瘤患者的术中疗效,减少并发症,在提高临床疗效和延长 PFS 方面表现出色。HIFU 可作为手术治疗的替代方法。